Logo der Universität Wien

Publikationen

Im Folgenden eine Übersicht über die im Zuge der Plattform "Translational Cancer Therapy Research" bisher entstandenen Publikationen: 

2016


Miklos W, Heffeter P, Pirker C, Hager S, Kowol CR, Schoonhoven SV, Stojanovic M, Keppler BK, Berger W.
Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling.
Oncotarget. 2016 in press


Fischer, B; Kryeziu, K; Kallus, S; Heffeter, P; Berger, W; Kowol, C R.; Keppler, B. K.
Nanoformulations of anticancer thiosemicarbazones to reduce methemoglobin formation and improve anticancer activity
RSC Advances 2016, 6(61), 55848-55859


Terenzi, A; Loetsch, D; van Schoonhoven, S; Roller, A; Kowol, C R.; Berger, W; Keppler, B K.; Barone, G.
Another step toward DNA selective targeting: NiII and CuII complexes of a Schiff base ligand able to bind gene promoter G-​quadruplexes
Dalton Trans. 2016, 45(18), 7758-7767


Bytzek AK, Koellensperger G, Keppler BK, G Hartinger C.
Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.
J Inorg Biochem. 2016 Jul;160:250-5.


Wilfinger N, Austin S, Scheiber-Mojdehkar B, Berger W, Reipert S, Praschberger M, Paur J, Trondl R, Keppler BK, Zielinski CC, Nowikovsky K.
Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy.
Oncotarget. 2016 Jan 12;7(2):1242-61.


Terenzi A, Pirker C, Keppler BK, Berger W.
Anticancer metal drugs and immunogenic cell death.
J Inorg Biochem. 2016 Jun 16. pii: S0162-0134(16)30184-2.


Novak MS, Büchel GE, Keppler BK, Jakupec MA.
Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
J Biol Inorg Chem. 2016 Jun;21(3):347-56


Kowol CR, Miklos W, Pfaff S, Hager S, Kallus S, Pelivan K, Kubanik M, Enyedy ÉA, Berger W, Heffeter P, Keppler BK.
Impact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention.
J Med Chem. 2016 Jul 28;59(14):6739-52.


Kubanik M, Kandioller W, Kim K, Anderson RF, Klapproth E, Jakupec MA, Roller A, Söhnel T, Keppler BK, Hartinger CG.
Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems.
Dalton Trans. 2016 Aug 16;45(33):13091-103.


Bijelic A, Theiner S, Keppler BK, Rompel A.
X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
J Med Chem. 2016 Jun 23;59(12):5894-903.


Henke H, Kryeziu K, Banfic J, Theiner S, Körner W, Brüggemann O, Berger W, Keppler BK, Heffeter P, Teasdale I.
Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.
Macromol Biosci. 2016 Aug;16(8):1239-49.


Legin AA, Theiner S, Schintlmeister A, Reipert S, Heffeter P, Jakupec MA, Varbanov HP, Kowol CR, Galanski M, Berger W, Wagner M, Keppler BK.
Multi-scale imaging of anticancer platinum(IV) compounds in murine tumor and kidney.
Chem Sci 2016, 7, 3052-3061


Göschl S, Varbanov HP, Theiner S, Jakupec MA, Galanski M, Keppler BK.
The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.
J Inorg Biochem. 2016 Jul;160:264-74.

 
Theiner S, Schreiber-Brynzak E, Jakupec MA, Galanski M, Koellensperger G, Keppler BK.
LA-ICP-MS imaging in multicellular tumor spheroids - a novel tool in the preclinical development of metal-based anticancer drugs.
 Metallomics. 2016 Apr;8(4):398-402


Pelivan K, Miklos W, Schoonhoven S, Koellensperger G, Gille L, Berger W, Heffeter P, Kowol CR, Keppler BK.
Differences in protein binding and excretion of Triapine and its Fe(III) complex. J Inorg Biochem 2016 Jul;160:61-9.

 
Terenzi A, Lötsch D, van Schoonhoven S, Roller A, Kowol CR, Berger W, Keppler BK, Barone G.
Another step toward DNA selective targeting: Ni(II) and Cu(II) complexes of a Schiff base ligand able to bind gene promoter G-quadruplexes.
Dalton Trans. 2016; 4;45(18):7758-67.

Flocke LS, Trondl R, Jakupec MA, Keppler BK.
Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines.
Invest New Drugs. 2016;34(3):261-8


Schmidlehner M, Flocke LS, Roller A, Hejl M, Jakupec MA, Kandioller W, Keppler BK.
Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics.
Dalton Trans. 2016;45(2):724-33.


Schreiber-Brynzak E, Pichler V, Heffeter P, Hanson B, Theiner S, Lichtscheidl-Schultz I, Kornauth C, Bamonti L, Dhery V, Groza D, Berry D, Berger W, Galanski M, Jakupec MA, Keppler BK.
Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation.
Metallomics. 2016;8(4):422-33.


2015

Kowol CR, Nagy NV, Jakusch T, Roller A, Heffeter P, Keppler BK, Enyedy ÉA.
Vanadium(IV/V) complexes of Triapine and related thiosemicarbazones: synthesis, solution equilibrium and bioactivity.
J Inorg Biochem. 2015;152:62-73.

 
Theiner S, Kornauth C, Van Schoonhoven S, Heffeter P, Berger W, Varbanov HP, Galanski M, Egger AE, Keppler BK.
Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.
Metallomics. 2015;7(8):1256-64.


Miklos M, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, Spitzwieser M, Englinger B, Van Schoonhoven S, Cichna-Markl M, Köllensperger G, Keppler BK, Berger W, Heffeter P.
Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.
Cancer Letters 2015. pii: S0304-3835(15)00164-0.


Theiner S, Varbanov HP, Galanski M, Egger AE, Berger W, Heffeter P, Keppler BK.
Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
JBIC 2015;20(1):89-99.


Höfer D, Varbanov HP, Legin A, Jakupec MA, Roller A, Galanski M, Keppler BK.
Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy.
J Inorg Biochem. 2015;153:259-71.


Schreiber-Brynzak E, Klapproth E, Unger C, Lichtscheidl-Schultz I, Göschl S, Schweighofer S, Trondl R, Dolznig H, Jakupec MA, Keppler BK.
Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs.
Invest New Drugs. 2015 Aug;33(4):835-47.


Pichler V, Göschl S, Schreiber-Brynzak E, Jakupec MA, Galanski M, Keppler BK.
Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines.
Metallomics. 2015 Jul;7(7):1078-90.


Habala L, Bartel C, Giester G, Jakupec MA, Keppler BK, Rompel A.
Complexes of N-hydroxyethyl-N-benzimidazolylmethylethylenediaminediacetic acid with group 12 metals and vanadium-Synthesis, structure and bioactivity of the vanadium complex.
J Inorg Biochem. 2015 Jun;147:147-52.


Hoffmeister BR, Hejl M, Adib-Razavi MS, Jakupec MA, Galanski M, Keppler BK.
Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.
Chem Biodivers. 2015 Apr;12(4):559-74.


Kuhn PS, Pichler V, Roller A, Hejl M, Jakupec MA, Kandioller W, Keppler BK.
Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential.
Dalton Trans. 2015 Jan 14;44(2):659-68.


Schmidlehner M, Flocke LS, Roller A, Hejl M, Jakupec MA, Kandioller W, Keppler BK.
Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics.
Dalton Trans. 2015 Dec 22;45(2):724-33.


Enyedy ÉA, Mészáros JP, Dömötör O, Hackl CM, Roller A, Keppler BK, Kandioller W.
Comparative solution equilibrium studies on pentamethylcyclopentadienyl rhodium complexes of 2,2'-bipyridine and ethylenediamine and their interaction with human serum albumin.
J Inorg Biochem. 2015 Nov;152:93-103.


Kuhn PS, Pichler V, Roller A, Hejl M, Jakupec MA, Kandioller W, Keppler BK.
Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential.
Dalton Trans. 2015 Jan 14;44(2):659-68.

 

2014


Trondl R, Heffeter P, Kowol CR, Jakupec MA, Berger W, Keppler BK.
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application.
Chem Sci 2014 5(8): 2925-2932


Heffeter P, Riabtseva A, Senkiv Y, Kowol CR, Körner W, Jungwith U, Mitina N, Keppler BK, Konstantinova T, Yanchuk I, Stoika R, Zaichenko A, Berger W.
Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019.
J Biomed Nanotechnol 2014 10(5):877-884.


Karnthaler-Benbakka C, Groza D, Kryeziu K, Pichler V, Roller A, Berger W, Heffeter P, Kowol CR.
Tumor-Targeting of EGFR Inhibitors via Hypoxia-Mediated Activation.
Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12930-5.


Jungwirth U, Gojo J, Tuder T, Walko G, Holcmann M, Schöfl T, Nowikovsky K, Wilfinger N, Schoonhoven S, Kowol CR, Lemmens-Gruber R, Heffeter P, Keppler BK, Berger W.
Calpain-mediated integrin deregulation as novel mode of action for the anticancer gallium compound KP46.
Mol Cancer Ther. 2014 Jul 31.


Varbanov H, Göschl S, Heffeter P, Theiner S; Roller A; Jensen F, Jakupec M, Berger W, Galanski M, Keppler BK.
A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.
J Med Chem. 2014 Aug 14;57(15):6751-64.

Egger AE, Theiner S, Kornauth C, Heffeter P, Berger W, Keppler BK, Hartinger CG.
Quantitative bio-imaging by LA–ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin-and KP1339-treated mice.
Metallomics. 2014 Aug 20;6(9):1616-25.


Meier SM, Babak MV, Keppler BK, Hartinger CG.
Efficiently Detecting Metallodrug-Protein Adducts: Ion Trap versus Time-of-Flight Mass Analyzers.
ChemMedChem. 2014 Jul;9(7):1351-5.


Senkiv Y, Riabtseva A, Heffeter P, Boiko N, Kowol CR, Jungwith U, Shlyakhtina Y, Garasevych SG, Mitina N, Berger W, Zaichenko A, Stoika R.
Enhanced anticancer activity and circumvention of resistance mechanisms by novel polymeric/ phospholipidic nanocarriers of doxorubicin.
J Biomed Nanotechnol. 2014, 10, 1369-1381


Dömötör O, Aicher S, Schmidlehner M, Novak MS, Roller A, Jakupec MA, Kandioller W, Hartinger CG, Keppler BK, Enyedy ÉA.
Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: synthesis, solution speciation and bioactivity.
J Inorg Biochem. 2014, 134, 57-65.


Trondl R, Flocke LS, Kowol CR, Heffeter P, Jungwirth U, Mair GE, Steinborn R, Enyedy ÉA, Jakupec MA, Berger W, Keppler BK.
Triapine and a more potent dimethyl derivative induce endoplasmic reticulum stress in cancer cells.
Mol Pharmacol. 2014, 85, 451-459 


Legin AA, Jakupec MA, Bokach NA, Tyan MR, Kukushkin VY, Keppler BK.
Guanidine platinum(II) complexes: synthesis, in vitro antitumor activity, and DNA interactions.
J Inorg Biochem. 2014, 133, 33-39.


Fischer B, Heffeter P, Kryeziu K, Gille L, Meier SM, Berger W, Kowol CR, Keppler BK.
Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation.
Dalton Trans. 2014, 43, 1096-1104

 

2013


Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Körner W, Jungwirth U, Mohr T, Keppler BK, Berger W.
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.
Eur J Cancer. 2013, 49, 3366-3375.


Pichler V, Göschl S, Meier SM, Roller A, Jakupec MA, Galanski M, Keppler BK.
Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes.
Inorg Chem. 2013, 52, 8151-8162

Enyedy EA, Sija E, Jakusch T, Hartinger CG, Kandioller W, Keppler BK, Kiss T.
Solution equilibria of anticancer ruthenium(II)-(?(6)-p-cymene)-hydroxy(thio)pyr(id)one complexes: impact of sulfur vs. oxygen donor systems on the speciation and bioactivity.
J Inorg Biochem. 2013, 127, 161-168

Meier SM, Novak M, Kandioller W, Jakupec MA, Arion VB, Metzler-Nolte N, Keppler BK, Hartinger CG.
Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
Chemistry. 2013, 19, 9297-9307

Grabmann G, Keppler BK, Hartinger CG
A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2'-deoxyguanosine 5'-monophosphate (dGMP).
Anal Bioanal Chem. 2013, 405, 6417-6424

Kryeziu, K.; Jungwirth, U.; Hoda, M. A.; Ferk, F.; Knasmüller, S.; Karnthaler-Benbakka, C.; Kowol, C. R.; Berger, W.; Heffeter, P.
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double strand break repair.
Mol. Cancer Ther. 2013, 12, 1073-1084 

Kurzwernhart, A.; Kandioller, W.; Enyedy, E. A.; Novak, M.; Jakupec, M. A.; Keppler, B. K.; Hartinger, C. G.
3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on RuII(arene) anticancer complexes with biologically active ligands
Dalton Trans. 2013, 42, 6193-6202

Kandioller, W.; Balsano, E.; Meier, S. M.; Jungwirth, U.; Goeschl, S.; Roller, A.; Jakupec, M. A.; Berger, W.; Keppler, B. K.; Hartinger, C. G.
Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity
Chem. Commun. 2013, 49, 3348-3350

Meier, S. M.; Hanif, M.; Adhireksan, Z.; Pichler, V.; Novak, M.; Jirkovsky, E.; Jakupec, M. A.; Arion, V. B.; Davey, C. A.; Keppler, B. K.; Hartinger, C. G.
Novel metal(ii) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents
Chem. Sci. 2013, 4, 1837-1846

Pichler, V.; Mayr, J.; Heffeter, P.; Doemoetoer, O.; Enyedy, E. A.; Hermann, G.; Groza, D.; Koellensperger, G.; Galanksi, M.; Berger, W.; Keppler, B. K.; Kowol, C. R.
Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery
Chem. Commun. 2013, 49, 2249-2251

Valiahdi, S. M.; Egger, A. E.; Miklos, W.; Jungwirth, U.; Meelich, K.; Nock, P.; Berger, W.; Hartinger, C. G.; Galanski, M.; Jakupec, M. A.; Keppler, B. K.
Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes
J. Biol. Inorg. Chem. 2013, 18, 249-260

Babak, M. V.; Meier, S. M.; Legin, A. A.; Adib R. S.; Roller, A.; Jakupec, M. A.; Keppler, B. K.; Hartinger, C. G.
Am(m)ines Make the Difference: Organoruthenium Am(m)ine Complexes and Their Chemistry in Anticancer Drug Development
Chem. Eur. J. 2013, 19, 4308-4318

Filak, L. K.; Goeschl, S.; Heffeter, P.; Ghannadzadeh S. K.; Egger, A. E.; Jakupec, M. A.; Keppler, B. K.; Berger, W.; Arion, V. B.
Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs. Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation
Organometallics 2013, 32, 903-914

Hummer, A. A.; Heffeter, P.; Berger, W.; Filipits, M.; Batchelor, D.; Buechel, G. E.; Jakupec, M. A.; Keppler, B. K.; Rompel, A.
X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019)
J. Med. Chem. 2013, 56, 1182-1196


2012


Pichler, V.; Heffeter, P.; Valiahdi, S. M.; Kowol, C. R.; Egger, A.; Berger, W.; Jakupec, M. A.; Galanski, M.; Keppler, B. K.
Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Glycol Moiety: Synthesis, Characterization, and Biological Activity
J. Med. Chem. 2012, 55, 11052-11061

Grabmann, G.; Meier, S. M.; Scaffidi-Domianello, Y. Y.; Galanski, M.; Keppler, B. K.; Hartinger, C. G.
Capillary zone electrophoresis and capillary zone electrophoresis-electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone oxime)platinum(II)] complexes in aqueous solutions
J. Chromatogr. A 2012, 1267, 156-161

Enyedy, E. A.; Domotor, O.; Varga, E.; Kiss, T.; Trondl, R.; Hartinger, C. G.; Keppler, B. K.
Comparative solution equilibrium studies of anticancer gallium(III) complexes of 8-hydroxyquinoline and hydroxy(thio)pyrone ligands
J. Inorg. Biochem. 2012, 117, 189-197.

Kurzwernhart, A.; Kandioller, W.; Baechler, S.; Bartel, C.; Martic, S.; Buczkowska, M.; Muehlgassner, G.; Jakupec, M. A.; Kraatz, H.-B.; Bednarski, P. J.; Arion, V. B.; Marko, D.; Keppler, B. K.; Hartinger, C. G.
Structure-Activity Relationships of Targeted RuII(?6-p-Cymene) Anticancer Complexes with Flavonol-Derived Ligands
J. Med. Chem. 2012, 55, 10512-10522

Muehlgassner, G.; Bartel, C.; Schmid, W. F.; Jakupec, M. A.; Arion, V. B.; Keppler, B. K.
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells
J. Inorg. Biochem. 2012, 116, 180-187

Ginzinger, W.; Egger, A.; Muehlgassner, G.; Arion, V. B.; Jakupec, M. A.; Galanski, M.; Berger, W.; Keppler, B. K.
Water-Soluble Cationic Derivatives of Indirubin, the Active Anticancer Component from Indigo naturalis
Chem. Biodivers. 2012, 9, 2175-2185

Henke, H.; Kandioller, W.; Hanif, M.; Keppler, B. K.; Hartinger, C. G.
Organometallic Ruthenium and Osmium Compounds of Pyridin-2- and -4-ones as Potential Anticancer Agents
Chem. Biodivers. 2012, 9, 1718-1727

Hoffmeister, B. R.; Adib-Razavi, M. S.; Jakupec, M. A.; Galanski, M.; Keppler, B. K.
Diamminetetrakis(carboxylato)platinum(IV) Complexes - Synthesis, Characterization, and Cytotoxicity
Chem. Biodivers. 2012, 9, 1840-1848.

Buechel, G. E.; Stepanenko, I. N.; Hejl, M.; Jakupec, M. A.; Keppler, B. K.; Heffeter, P.; Berger, W.; Arion, V. B.
Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity
J. Inorg. Biochem. 2012, 113, 47-54.

Mühlgassner, G.; Bartel, C.; Schmid, W. F.; Jakupec, M. A.; Arion, V. B.; Keppler, B. K.
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells.
J. Inorg. Biochem. 2012, accepted

Scaffidi-Domianello, Y. Yu.; Legin, A. A.; Jakupec, M. A.; Roller, A.; Kukushkin, V. Yu.; Galanski, M.; Keppler, B. K.
Novel Oximato-Bridged Platinum(II) Di- and Trimer(s): Synthetic, Structural, and in vitro Anticancer Activity Studies.
Inorg. Chem. 2012, accepted

Henke, H.; Kandioller, W.; Hanif, M.; Keppler, B. K.; Hartinger, C. G.
Organometallic Ru and Os compounds of 2- and 4-Pyridones as Potential Anticancer Agents.
Chem. Biodiv. 2012, accepted

Kurzwernhart, A.; Kandioller, W.; Bartel, C.; Bächler, S.; Trondl, R.; Mühlgassner, G.; Jakupec, M. A.; Arion, V. B.; Marko, D.; Keppler, B. K.; Hartinger, C. G.
Targeting the DNA-topoisomerase complex in a doublestrike approach with a topoisomerase inhibiting moiety and covalent DNA binder.
Chem. Commun. 2012, in print

Heffeter, P.; Pirker, C.; Kowol, C. R.; Herrman, G.; Dornetshuber, R.; Miklos, W.; Jungwirth, U.; Koellensperger, G.; Keppler, B. K.; Berger, W.
Impact of terminal dimethylation on the resistance profile of a-N-heterocyclic thiosemicarbazones.
Biochem. Pharmacol. 2012, in print

Ginzinger, W.; Mühlgassner, G.; Arion, V. B.; Jakupec, M. A.; Roller, A.; Galanski, M.; Reithofer, M.; Berger, W.; Keppler, B. K.
A SAR Study of Novel Antiproliferative Ruthenium and Osmium Complexes with Quinoxalinone Ligands in Human Cancer Cell Lines
J. Med. Chem. 2012, 55, 3398-3413. 

Jungwirth, U.; Xanthos, D. N.; Gojo, J.; Bytzek, A. K.; Koerner, W.; Heffeter, P.; Abramkin, S. A.; Jakupec, M. A.; Hartinger, C. G.; Windberger, U.
Anticancer activity of methyl-substituted oxaliplatin analogs
Mol. Pharmacol. 2012, 81(5), 719-728. 

Kowol, C. R.; Heffeter, P.; Miklos, W.; Gille, L.; Trondl, R.; Cappellacci, L.; Berger, W.; Keppler, B. K.
Mechanisms underlying reductant-induced ROS formation by anticancer copper(II) thiosemicarbazone compounds
J. Biol. Inorg. Chem. 2012, 17, 409-423.

Meier, S. M.; Hanif, M.; Kandioller, W.; Keppler, B. K.; Hartinger, C. G.
Biomolecule binding vs. anticancer activity: Reactions of Ru(arene)[(thio)pyr(id)one] compounds with amino acids and proteins.
J. Inorg. Biochem. 2012, 108, 91-95.

Bartel, C.; Bytzek, A. K.; Scaffidi-Domianello, Y. Y.; Grabmann, G.; Jakupec, M. A.; Hartinger, C. G.; Galanski, M.; Keppler, B. K.
Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds.
J. Biol. Inorg. Chem. 2012, 17, 465-474.

Meier, S. M.; Tsybin, Y. O.; Dyson, P. J.; Keppler, B. K.; Hartinger, C. G.
Fragmentation methods on the balance: unambiguous top-down mass spectrometric characterization of oxaliplatin-ubiquitin binding sites.
Anal. Bioanal. Chem. 2012, 402, 2655-2662.

 

2011

 

Bytzek, A. K.; Boeck, K.; Hermann, G.; Hann, S.; Keppler, B. K.; Hartinger, C. G.; Koellensperger, G.
LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.
Metallomics 2011, 3, 1049-1055.

Scaffidi-Domianello, Y. Y.; Legin, A. A.; Jakupec, M. A.; Arion, V. B.; Kukushkin, V. Yu.; Galanski, M.; Keppler, B. K.
Synthesis, Characterization, and Cytotoxic Activity of Novel Potentially pH-Sensitive Nonclassical Platinum(II) Complexes Featuring 1,3-Dihydroxyacetone Oxime Ligands.
Inorg. Chem. 2011, 50, 10673-10681.

Bartel, C.; Egger, A.; Jakupec, M, A.; Heffeter, P.; Galanski, M.; Berger, W.; Keppler, B, K.
Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
J. Biol. Inorg. Chem. 2011, 16, 1205-1215.

Metzner, T.; Bedeir, A.; Held, G.; Peter-Vörösmarty, B.; Ghassemi, S.; Heinzle, C.; Spiegl-Kreinecker, S.; Marian, B.; Holzmann, K.; Grasl-Kraupp, B.; Pirker, C.; Micksche, M.; Berger, W.; Heffeter, P.; Grusch, M.
Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition
J. Invest. Dermatol. 2011, 131, 2087-2095.

Pichler, V.; Valiahdi, S-M.; Jakupec, M. A.; Arion, V. B.; Galanski, M.; Keppler, B. K.
Mono-carboxylated diaminedichloridoplatinum(IV) complexes – selective synthesis, characterization, and cytotoxicity 
Dalton Trans. 2011, 40, 8187-8192.

Jungwirth, U.; Kowol, C. R.; Keppler, B. K.; Hartinger, C. G.; Berger, W.; Heffeter, P.
Anticancer activity of metal complexes: involvement of redox processes
Antioxid. Redox Signal. 2011, 15, 1085-1127.

Kandioller, W.; Kurzwernhart, A.; Hanif, M.; Meier, S. M.; Henke, H.; Keppler, B. K.; Hartinger, C. G.
(Thio)Pyr(id)ones and metals: from natural products to metal-based drugs
J. Organomet. Chem. 2011, 696, 999-1010.

Hanif, M.; Meier, S. M.; Kandioller, W.; Bytzek, A.; Hejl, M.; Hartinger, C. G.; Nazarov, A. A.; Arion, V. B.; Jakupec, M. A.; Dyson, P. J.; Keppler, B. K.
From Hydrolytically Labile to Hydrolytically Stable Ru(II)-Arene Anticancer Complexes with Carbohydrate-Derived Co-ligands
J. Inorg. Biochem. 2011, 105, 224.231.

 

2010

 

Filak, L. K.; Muehlgassner, G.; Jakupec, M. A.; Heffeter, P.; Berger, W.; Arion, V. B.; Keppler, B. K.
Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy.
J. Biol. Inorg. Chem. 2010, 15, 903-918. 

Hanif, M.; Henke, H.; Meier, S. M.; Martic, S.; Labib, M.; Kandioller, W.; Jakupec, M. A.; Arion, V. B.; Kraatz, H-B.; Keppler, B. K.; Hartinger, C. G.
Is the Reactivity of M(II)–Arene Complexes of 3-Hydroxy-2(1H)-pyridones to Biomolecules the Anticancer Activity Determining Parameter?
Inorg. Chem. 2010, 49, 7953-7963.

Heffeter, P.; Boeck, K.; Atil, B.; Hoda, M. A. R.; Koerner, W.; Bartel, C.; Jungwirth, U.; Keppler, B. K.; Micksche, M.; Berger, W.; Koellensperger, G.
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
J. Biol. Inorg. Chem. 2010, 15, 737-748. 

Hanif, M,; Nazarov, A. A.; Hartinger, C. G.; Kandioller, W.; Jakupec, M. A.; Arion, V. B.; Dyson, P. J.; Keppler, B. K.
Osmium(II) versus Ruthenium(II)-Arene Carbohydrate-based Anticancer Compounds: Similarities and Differences
Dalton. Trans. 2010, 39, 7345-7352.

Abramkin, S.A.; Jungwirth, U.; Valiahdi, S.M.; Dworak, C.; Habala, L.; Meelich, K.; Berger, W.; Jakupec, M.A.; Hartinger, C.G.; Nazarov, A.A.; Galanski, M.; Keppler, B.K.
{(1R,2R,4R )-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II) – a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo
J. Med. Chem. 2010, 53, 7356-7364.

Hanif, M.; Schaaf, P.; Kandioller, W.; Hejl, M.; Jakupec, M. A.; Roller, A.; Keppler, B. K.; Hartinger, C. G.
Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol RutheniumII–(?6-Arene) Complexes
Aust. J. Chem. 2010, 63, 1521–1528.

Scaffidi-Domianello, Y.; Meelich, K.; Jakupec, M.A.; Arion, V.B.; Kukushkin, V.Yu.; Galanski, M.; Keppler, B.K.
Novel cis- and trans-configured bis(oxime)platinum(II) complexes – synthesis, characterization, and cytotoxic activity
Inorg. Chem. 2010, 49, 5669-5678.

 

2009


Kowol, C. R.; Trondl, R.; Heffeter, P.; Arion, V. B.; Jakupec, M. A.; Roller, A.; Galanski, M.; Berger, W.; Keppler, B. K.
Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation.
J. Med. Chem. 2009, 52, 5032-5043.

 

 

Universität Wien
Forschungsplattform Translational Cancer Therapy Research

Währinger Straße 42
1090 Wien
T: +43-1-4277-526 01
F: +43-1-4277-95 26
Universität Wien | Universitätsring 1 | 1010 Wien | T +43-1-4277-0
Letzte Änderung: 20.09.2016 - 13:52